The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams
- PMID: 32504098
- PMCID: PMC7553895
- DOI: 10.1007/s00330-020-06945-z
The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams
Abstract
Objectives: MRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams.
Methods: This retrospective study included 183 consecutive, histologically proven, suspicious (MR BI-RADS 4) lesions detected within our local high-risk screening program. All lesions were evaluated according to the Kaiser score for breast MRI by three readers blinded to the final histopathological diagnosis. The Kaiser score ranges from 1 (lowest, cancer very unlikely) to 11 (highest, cancer very likely) and reflects increasing probabilities of malignancy, with scores greater than 4 requiring biopsy. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic accuracy.
Results: There were 142 benign and 41 malignant lesions, diagnosed in 159 patients (mean age, 43.6 years). Median Kaiser scores ranged between 2 and 5 in benign and 7 and 8 in malignant lesions. For all lesions, the Kaiser score's accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2. The sensitivity of the Kaiser score was high, between 95.1 and 97.6% for all lesions, and was best in mass lesions. Application of the Kaiser score threshold for malignancy (≤ 4) could have potentially avoided 64 (45.1%) to 103 (72.5%) unnecessary biopsies in 142 benign lesions previously classified as BI-RADS 4.
Conclusions: The use of Kaiser score in high-risk MRI screening reliably excludes malignancy in more than 45% of contrast-enhancing lesions classified as BI-RADS 4.
Key points: • The Kaiser score shows high diagnostic accuracy in identifying malignancy in contrast-enhancing lesions in patients undergoing high-risk screening for breast cancer. • The application of the Kaiser score may avoid > 45% of unnecessary breast biopsies in high-risk patients. • The Kaiser score aids decision-making in high-risk breast cancer MRI screening programs.
Keywords: Breast cancer; Clinical; Decision support systems; Magnetic resonance imaging; Screening; Sensitivity and specificity.
Conflict of interest statement
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Figures






Similar articles
-
Impact of the Kaiser score on clinical decision-making in BI-RADS 4 mammographic calcifications examined with breast MRI.Eur Radiol. 2020 Mar;30(3):1451-1459. doi: 10.1007/s00330-019-06444-w. Epub 2019 Dec 3. Eur Radiol. 2020. PMID: 31797077 Free PMC article.
-
Value of contrast-enhanced mammography combined with the Kaiser score for clinical decision-making regarding tomosynthesis BI-RADS 4A lesions.Eur Radiol. 2022 Nov;32(11):7439-7447. doi: 10.1007/s00330-022-08810-7. Epub 2022 May 31. Eur Radiol. 2022. PMID: 35639141
-
An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies.Eur Radiol. 2021 Aug;31(8):5866-5876. doi: 10.1007/s00330-021-07787-z. Epub 2021 Mar 20. Eur Radiol. 2021. PMID: 33744990 Free PMC article.
-
Can structured integration of BI-RADS criteria by a clinical decision rule reduce the number of unnecessary biopsies in BI-RADS 4 lesions? A systematic review and meta-analysis.Eur Radiol. 2025 Mar;35(3):1504-1513. doi: 10.1007/s00330-024-11274-6. Epub 2024 Dec 18. Eur Radiol. 2025. PMID: 39694886 Free PMC article.
-
Improved Differential Diagnosis Based on BI-RADS Descriptors and Apparent Diffusion Coefficient for Breast Lesions: A Multiparametric MRI Analysis as Compared to Kaiser Score.Acad Radiol. 2023 Sep;30 Suppl 2:S93-S103. doi: 10.1016/j.acra.2023.03.035. Epub 2023 May 24. Acad Radiol. 2023. PMID: 37236897 Review.
Cited by
-
Reduction of biopsy rate in BI-RADS4 breast lesions: potential of an abbreviated advanced DWI protocol.Eur Radiol. 2025 Apr 24. doi: 10.1007/s00330-025-11604-2. Online ahead of print. Eur Radiol. 2025. PMID: 40272489
-
Evaluation of the differentiation of benign and malignant breast lesions using synthetic relaxometry and the Kaiser score.Front Oncol. 2022 Oct 11;12:964078. doi: 10.3389/fonc.2022.964078. eCollection 2022. Front Oncol. 2022. PMID: 36303839 Free PMC article.
-
Can DWI provide additional value to Kaiser score in evaluation of breast lesions.Eur Radiol. 2022 Sep;32(9):5964-5973. doi: 10.1007/s00330-022-08674-x. Epub 2022 Mar 31. Eur Radiol. 2022. PMID: 35357535
-
A Comparative Assessment of MR BI-RADS 4 Breast Lesions With Kaiser Score and Apparent Diffusion Coefficient Value.Front Oncol. 2021 Dec 2;11:779642. doi: 10.3389/fonc.2021.779642. eCollection 2021. Front Oncol. 2021. PMID: 34926290 Free PMC article.
-
Diagnostic value of Kaiser score combined with breast vascular assessment from breast MRI for the characterization of breast lesions.Front Oncol. 2023 Jul 6;13:1165405. doi: 10.3389/fonc.2023.1165405. eCollection 2023. Front Oncol. 2023. PMID: 37483510 Free PMC article.
References
-
- Bennani-Baiti B, Baltzer PA (2017) MR imaging for diagnosis of malignancy in mammographic microcalcifications: a systematic review and meta-analysis. Radiology 283:692–701 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical